Dtsch Med Wochenschr 2008; 133(48): 2527-2529
DOI: 10.1055/s-0028-1100952
Kommentar | Commentary
Intensivmedizin
© Georg Thieme Verlag KG Stuttgart · New York

Hydrokortison auf der Intensivstation: Wer sollte behandelt werden und wann? [1]

Hydrocortisone in intensive care medicine: who should be treated and when? P. Möhnle1 , F. Weis1 , E. Kilger1 , J. Briegel1
  • 1Klinik für Anästhesiologie der Universität München
Further Information

Publication History

eingereicht: 12.6.2008

akzeptiert: 1.9.2008

Publication Date:
19 November 2008 (online)

1 Herrn Prof. Dr. Dr. h. c. Klaus Peter zum 70. Geburtstag gewidmet.

Literatur

  • 1 Annane D, Maxime V, Ibrahim F, Alvarez J C, Abe E, Boudou P. Diagnosis of adrenal insufficiency in severe sepsis and septic shock.  Am J Respir Crit Care Med. 2006;  174 1319-1326
  • 2 Annane D, Sebille V, Bellissant E. Ger-Inf-05 Study Group . Effect of low doses of Corticosteroids in septic shock patients with or without early acute respiratory distress syndrome.  Crit Care Med. 2006;  34 22-30
  • 3 Annane D, Sebille V, Charpentier C. et al . Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.  JAMA. 2002;  288 862-871
  • 4 Annane D, Sébille V, Troché G, Raphaël J C, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin.  JAMA. 2000;  283 1038-1045
  • 5 Bollaert P E, Charpentier C, Levy B. et al . Reversal of late septic shock with supraphysiologic doses of hydrocortisone.  Crit Care Med. 1998;  26 645-650
  • 6 Briegel J, Forst H, Haller M. et al . Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, singlecenter study.  Crit Care Med. 1999;  27 723-732
  • 7 Chawla K, Kupfer Y, Tessler S. Hydrocortisone reverses refractory septic shock.  Crit Care Med. 1999;  27 A33
  • 8 Confalonieri M, Urbino R, Potena A. et al . Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study.  Am J Respir Crit Care Med. 2005;  171 242-248
  • 9 Eklund A, Leppaniemi A, Kemppainen E, Pettila V. Vasodilatory shock in severe acute pancreatitis without sepsis: is there any place for hydrocortisone treatment?.  Acta Anaesthesiol Scand. 2005;  49 379-384
  • 10 Halonen J, Halonen P, Järvinen O. et al . Corticosteroids for the prevention of atrial fibrillation after cardiac surgery. A randomized controlled trial.  JAMA. 2007;  297 1562-1567
  • 11 Hoen S, Mazoit J X, Asehnoune K. et al . Hydrocortisone increases the sensitivity to alpha1-adrenoceptor stimulation in humans following hemorrhagic shock.  Crit Care Med. 2005;  33 2737-2743
  • 12 Keh D, Boehnke T, Weber-Carstens S. et al . Immunologic and hemodynamic effects of „low dose” hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study.  Am J Respir Crit Care Med. 2003;  167 512-520
  • 13 Kilger E, Weis F, Briegel J. et al . Stress doses of hydrocortisone reduce severe systemic inflammatory response syndrome and improve early outcome in a risk group of patients after cardiac surgery.  Crit Care Med. 2003;  31 1068-1074
  • 14 Lipiner-Friedmann D, Sprung C L, Laterre P F. et al, Corticus Study Group . Adrenal function in sepsis: The retrospective Corticus cohort study.  Crit Care Med. 2007;  35 1012-1018
  • 15 Meduri G U, Golden E, Freire A X. et al . Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial.  Chest. 2007;  131 954-963
  • 16 Meduri G U, Headley A S, Golden E. et al . Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial.  JAMA. 1998;  280 159-165
  • 17 Meduri G U, Marik P E, Chrousos G P. et al . Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature.  Intensive Care Med. 2008;  34 61-69
  • 18 Meduri G U, Tolley E A, Chrousos G P, Stentz F. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids.  Am J Respir Crit Care Med. 2002;  165 983-991
  • 19 Muller C A, Vogeser M, Belyaev O. et al . Role of endogenous glucocorticoid metabolism in human acute pancreatitis.  Crit Care Med. 2006;  34 1060-1066
  • 20 Oppert M, Reinicke A, Graf K J. et al . Plasma cortisol levels before and during „low-dose” hydrocortisone therapy and their relationship to hemodynamic improvement in patients with septic shock.  Intensive Care Med. 2000;  26 1747-1755
  • 21 Oppert M, Schindler R, Husung C. et al . Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock.  Crit Care Med. 2005;  33 2457-2464
  • 22 Sprung C L, Annane D, Keh D. et al, CORTICUS Study Group . Hydrocortisone therapy for patients with septic shock.  N Engl J Med. 2008;  358 111-124
  • 23 Steinberg K P, Hudson L D, Goodman R B. et al . National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of Corticosteroids for persistent acute respiratory distress syndrome.  N Engl J Med. 2006;  354 1671-1684
  • 24 Weis F, Kilger E, Beiras-Fernandez A. et al . Association between vasopressor dependence and early outcome in patients after cardiac surgery.  Anaesthesia. 2006;  61 938-942

1 Herrn Prof. Dr. Dr. h. c. Klaus Peter zum 70. Geburtstag gewidmet.

Dr. med. Patrick Möhnle

Klinik für Anästhesiologie der Universität München

Marchioninistr. 15

81377 München

Phone: 089/7095-3410

Fax: 089/7095-8886

Email: patrick.moehnle@med.uni-muenchen.de

    >